Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis
Background: It is not uncommon to see that a large proportion of patients with cirrhosis due to Nonalcoholic steatohepatitis (NASH) never had any prior evaluation or diagnosis of liver disease, and most of the times their first clinical presentation is decompensated cirrhosis. Acknowledging incidental finding of fatty liver on abdominal imaging and identifying patients at risk of having advanced liver fibrosis may help in preventing its progression to cirrhosis.
Aim: We aimed to increase acknowledgement and improve evaluation of steatosis via radiology recommendation to consider hepatology referral, and to identify the predictors of hepatology referral and significant fibrosis.
Methods: We performed a retrospective study of 812 patients with hepatic steatosis tagged on ultrasound (US), over 18 months, at a single center. Patients with secondary causes of fatty liver were excluded. We evaluated the yield of this intervention and factors correlated with hepatology referral and presence of significant fibrosis.
Results: Diagnosis of fatty liver was acknowledged for 69% of patients with tagged US, although only 29% were ultimately seen by hepatology. Patients who had US ordered by a primary care provider (PCP) were more likely to have hepatology evaluation (64.8% vs 56.9%, P = 0.0183). Sixty-six percent of patients seen by hepatology had elevated alanine transaminase (ALT) compared to 52% not seen by hepatology (P < 0.0005). Among patients further evaluated, 53% underwent staging, and 18% had ≥ stage 2 (F2) fibrosis. Type II diabetes (DMII) correlated with significant to advanced fibrosis (43.5% vs 21.4%, P = 0.0357), while ALT and Body Mass Index (BMI) did not.
Conclusions: Tagging US reports led to clinical acknowledgement of fatty liver in 7 of 10 patients, although fewer than 1 in 3 had further hepatology evaluation. Of those who underwent staging for incidentally noted steatosis, 18% had significant fibrosis, suggesting that we are failing to evaluate patients with potentially advanced liver disease.
Relevance for patients: Identifying incidental finding of fatty liver on US provides a unique opportunity in diagnosing liver fibrosis at an early stage and can help prevent its progression to cirrhosis. Primary care providers should consider using noninvasive scoring systems on a regular basis to assess the risk of fibrosis in patients with fatty liver, and timely referral to hepatology should be provided in patients at high risk of having advanced fibrosis.
[1] Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the Prevalence of the most Common Causes of Chronic Liver Diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-30.e1; quiz e60.
[2] Caldwell SH, Crespo DM. The Spectrum Expanded: Cryptogenic Cirrhosis and the Natural History of Nonalcoholic Fatty Liver Disease. J Hepatol 2004;40:578.
[3] Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, et al. Characterization of Hepatocellular Carcinoma (HCC) in Non-alcoholic Fatty Liver Disease (NAFLD) Patients without Cirrhosis. Hepatol Int 2016;10:632-9.
[4] Kleiner DE, Brunt EM. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Semin Liver Dis 2012;32:3.
[5] Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
[6] Bacon BR, Farahvash MJ, Janney CG, NeuschwanderTetri BA. Nonalcoholic Steatohepatitis: An Expanded Clinical Entity. Gastroenterology 1994;107:1103.
[7] Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328.
[8] Sheth SG, Gordon FD, Chopra S. Nonalcoholic Steatohepatitis. Ann Intern Med 1997;126:137.
[9] Suzuki A, Diehl MA. Nonalcoholic Steatohepatitis. Annu Rev Med 2017;68:85-98.
[10] Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Hepatology 2017;65:1557-65.
[11] Schuppan D, Surabattula R, Wang XY. Determinant of Fibrosis Progression and Regression in NASH. J Hepatol 2018;68:238-50.
[12] Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in Recognition and Evaluation of Incidentally Identified Hepatic Steatosis. Dig Dis Sci 2015;60:333-8.
[13] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35.
[14] Bertot LC, Adams LA. Natural Course of Non-alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:774.
[15] Mahady SE, Macaskill P, Craig JC, Wong GL, Chu WC, Chan HL, et al. Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals with a Low Prevalence of Fibrosis. Clin Gastroenterol Hepatol 2017;15:1453-60.
[16] Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study. Hepatology 2014;60:1920-8.
[17] Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis is Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30.
[18] Kutaiba N, Richmond D, Morey M, Brennan D, Rotella JA, Ardalan Z, et al. Incidental Hepatic Steatosis on Unenhanced Computed Tomography Performed for Suspected Renal Colic: Gaps in Reporting and Documentation. J Med Imaging Radiat Oncol 2019;63:431-8.
[19] Kutaiba N, Rotella JA, Ardalan Z, Testro A. Incidental Hepatic Steatosis in Radiology Reports: A Survey of Emergency Department Clinicians Perspectives and Current Practice. J Med Imaging Radiat Oncol 2019;63:573-9.
[20] Wells MM, Li Z, Addeman B, McKenzie CA, Mujoomdar A, Beaton M, et al. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Can J Gastroenterol Hepatol 2016;2016:4930987.
[21] Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis A Review. JAMA 2020;323:1175-83.
[22] Verma S, Jensen D, Hart J, Mohanty SR. Predictive Value of ALT Levels for Non-alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD). Liver Int 2013;33:1398-405.
[23] Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated with Normal ALT Values. Hepatology 2003;37:1286-92.